Page last updated: 2024-08-23

raloxifene hydrochloride and Apoplexy

raloxifene hydrochloride has been researched along with Apoplexy in 20 studies

Research

Studies (20)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	14 (70.00)	29.6817
2010's	6 (30.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hamaya, E; Sowa, H	1
Urushihara, H	1
Abramson, BL; Amewou-Atisso, M; Barrett-Connor, E; Collins, P; Dowsett, SA; Geiger, MJ; Grady, D; Kornitzer, M; Mosca, L; Paganini-Hill, A; Wenger, N	1
Barrett-Connor, E; Cox, DA; Grady, D; Mitlak, B; Mosca, L; Song, J	1
de Villiers, TJ	1
Fu, R; Griffin, JC; Humphrey, L; Nelson, HD; Nygren, P; Smith, ME	1
Becker, C	1
Inoue, D	1
Mosekilde, L; Pinholt, EM; Rejnmark, L; Schwartz, K; Vestergaard, P	1
Barrett-Connor, E; Cauley, JA; Cox, DA; Geiger, MJ; Kulkarni, PM; Sashegyi, A	1
Hamaya, E; Kobayashi, H	1
Wooltorton, E	1
Barrett-Connor, E; Collins, P; Geiger, MJ; Grady, D; Kornitzer, M; McNabb, MA; Mosca, L; Wenger, NK	1
Matsumoto, T	1
Wenger, NK	1
Avigan, M; Green, L; Wyeth, J	1
Okazaki, R	1
Friedrich, MJ	1
Anderson, PW; Barrett-Connor, E; Cox, DA; Grady, D; Harper, KD; Hoszowski, K; Rautaharju, P; Sashegyi, A	1

Reviews

7 review(s) available for raloxifene hydrochloride and Apoplexy

Article	Year
Clinical issues regarding cardiovascular disease and selective estrogen receptor modulators in postmenopausal women. Climacteric : the journal of the International Menopause Society, 2009, Volume: 12 Suppl 1 Topics: Cardiovascular Diseases; Female; Humans; Indoles; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Stroke; Tamoxifen; Tetrahydronaphthalenes; Venous Thromboembolism	2009
Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer. Annals of internal medicine, 2009, Nov-17, Volume: 151, Issue:10 Topics: Breast Neoplasms; Endometrial Neoplasms; Estrogen Receptor Modulators; Female; Fractures, Bone; Humans; Norpregnenes; Raloxifene Hydrochloride; Stroke; Tamoxifen; Thromboembolism	2009
[Effects of SERMs on bone health. Raloxifene effects on breast cancer and cardiovascular events]. Clinical calcium, 2010, Volume: 20, Issue:3 Topics: Arteriosclerosis; Breast Neoplasms; Female; Humans; Osteoporosis, Postmenopausal; Pulmonary Embolism; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Stroke; Venous Thrombosis	2010
[Raloxifene hydrochloride (Evista Tablet 60 mg) for postmenopausal osteoporosis: mode of action and clinical efficacy]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2005, Volume: 125, Issue:1 Topics: Animals; Bone and Bones; Bone Density; Bone Remodeling; Bone Resorption; Breast Neoplasms; Controlled Clinical Trials as Topic; Coronary Disease; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Stroke; Transcription Factors	2005
[Selective estrogen receptor modulators (SERMs)]. Clinical calcium, 2006, Volume: 16, Issue:9 Topics: Breast Neoplasms; Female; Humans; Organ Specificity; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Spinal Fractures; Stroke	2006
[Menopausal hormone therapy and cardiovascular disease]. Revista espanola de cardiologia, 2006, Volume: 59, Issue:10 Topics: Age Factors; Aged; Breast Neoplasms; Cardiovascular Diseases; Cohort Studies; Coronary Angiography; Coronary Disease; Electrocardiography; Estrogen Replacement Therapy; Estrogens; Female; Follow-Up Studies; Heart Rate; Humans; Life Style; Mammography; Meta-Analysis as Topic; Middle Aged; Myocardial Infarction; Progestins; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Stroke; Time Factors	2006
[Effects of SERM on the cardiovascular system]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Nov-28, Volume: 65 Suppl 9 Topics: Arteriosclerosis; Cardiovascular Diseases; Clinical Trials as Topic; Female; Humans; Hyperlipidemias; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Stroke	2007

Trials

4 trial(s) available for raloxifene hydrochloride and Apoplexy

Article	Year
Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease. Stroke, 2009, Volume: 40, Issue:1 Topics: Comorbidity; Coronary Artery Disease; Humans; Incidence; Middle Aged; Mortality; Postmenopause; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Smoking; Stroke; Treatment Outcome; Venous Thromboembolism	2009
Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2004, Volume: 19, Issue:8 Topics: Aged; Breast Neoplasms; Coronary Disease; Double-Blind Method; Female; Hip Fractures; Humans; Middle Aged; Osteoporosis, Postmenopausal; Proportional Hazards Models; Pulmonary Embolism; Raloxifene Hydrochloride; Risk Assessment; Stroke; Treatment Outcome	2004
Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. The New England journal of medicine, 2006, Jul-13, Volume: 355, Issue:2 Topics: Aged; Breast Neoplasms; Coronary Disease; Double-Blind Method; Female; Humans; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Stroke; Thromboembolism	2006
Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA, 2002, Feb-20, Volume: 287, Issue:7 Topics: Aged; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Ischemic Attack, Transient; Lipoproteins; Myocardial Ischemia; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Stroke; Survival Analysis	2002

Other Studies

9 other study(ies) available for raloxifene hydrochloride and Apoplexy

Article	Year
Re: Raloxifene and stroke risks in Japanese postmenopausal women with osteoporosis on postmarketing surveillance. Menopause (New York, N.Y.), 2014, Volume: 21, Issue:1 Topics: Bone Density Conservation Agents; Female; Humans; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Stroke	2014
In reply. Menopause (New York, N.Y.), 2014, Volume: 21, Issue:1 Topics: Bone Density Conservation Agents; Female; Humans; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Stroke	2014
Raloxifene and risk for stroke based on the framingham stroke risk score. The American journal of medicine, 2009, Volume: 122, Issue:8 Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Spinal Fractures; Stroke	2009
Another selective estrogen-receptor modulator for osteoporosis. The New England journal of medicine, 2010, Feb-25, Volume: 362, Issue:8 Topics: Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Coronary Disease; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Pyrrolidines; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Stroke; Tamoxifen; Tetrahydronaphthalenes; Venous Thromboembolism	2010
Stroke in relation to use of raloxifene and other drugs against osteoporosis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2011, Volume: 22, Issue:4 Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Case-Control Studies; Denmark; Dose-Response Relationship, Drug; Drug Administration Schedule; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Risk Assessment; Stroke	2011
My doctor wanted me to start taking Evista (raloxifene hydrochloride) for osteoporosis, but I'm worried because the drug is linked to a risk of blood clots. I have mild hypertension that I manage with medications, diet and exercise. Do you think the drug Heart advisor, 2010, Volume: 13, Issue:5 Topics: Bone Density Conservation Agents; Diet; Exercise; Female; Humans; Hypertension; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Stroke; Thrombosis	2010
Osteoporosis treatment: raloxifene (Evista) and stroke mortality. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2006, Jul-18, Volume: 175, Issue:2 Topics: Aged; Bone Density Conservation Agents; Female; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Stroke	2006
U.S. Food and drug administration analysis of strokes associated with raloxifene. Obstetrics and gynecology, 2007, Volume: 109, Issue:4 Topics: Contraindications; Drug Approval; Female; Humans; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Stroke; United States; United States Food and Drug Administration	2007
Teasing out effects of estrogen on the brain. JAMA, 2002, Jan-02, Volume: 287, Issue:1 Topics: Alzheimer Disease; Animals; Brain; Cognition; Estrogen Receptor alpha; Estrogens; Hippocampus; Humans; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Stroke	2002